New drug combo aims to outsmart tough leukemia without chemo
NCT ID NCT04329325
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding blinatumomab (an immunotherapy) to standard targeted therapy (dasatinib) can improve treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to achieve a deep molecular response without using traditional chemotherapy. The study involves 17 participants and focuses on safety and how well the combination works as consolidation and maintenance therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blinatumomab (a type of immunotherapy) and dasatinib (a targeted therapy pill)
What this could lead to
If successful, this combination could become a more effective, chemotherapy-free treatment option for people with Ph+ ALL, potentially leading to deeper remissions.
What could go wrong
This is a small, early-phase trial with only 17 participants, so results may not apply to everyone. The combination may cause serious side effects, and it is not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mount Sinai Hospital
New York, New York, 10029, United States